JP7744764B2 - Blood sugar level suppressant - Google Patents
Blood sugar level suppressantInfo
- Publication number
- JP7744764B2 JP7744764B2 JP2021107773A JP2021107773A JP7744764B2 JP 7744764 B2 JP7744764 B2 JP 7744764B2 JP 2021107773 A JP2021107773 A JP 2021107773A JP 2021107773 A JP2021107773 A JP 2021107773A JP 7744764 B2 JP7744764 B2 JP 7744764B2
- Authority
- JP
- Japan
- Prior art keywords
- blood glucose
- brown algae
- glucose level
- inhibitor
- polyvalent metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、血糖値上昇抑制剤に関する。 The present invention relates to an agent for suppressing blood glucose elevation.
食事により血糖値が上昇してもインスリンの働きによって過剰な血糖値の上昇は抑制され、血糖値は一定の範囲にコントロールされている。しかし、糖尿病を発症するとインスリンの分泌や働きが抑制されることで、血糖値が正常範囲へ下がりづらくなり、高血糖による動脈硬化等の合併症を引き起こすリスクが指摘されている。また、糖尿病とは診断されていないものの、食後の血糖値が急激に上昇したり、血糖値が高めの状態が続けば、同様の疾患を発症するおそれも指摘されている。このような糖尿病、高血糖は、食生活の乱れや運動不足に起因することが多く、生活習慣を見直すことで、これらを予防、改善することが期待されている。最近では、食生活の改善を目的に、安全で日々の生活で摂取しやすい食品に由来する機能性成分に着目した製品開発も進んでおり、特に血糖値上昇抑制に関与する成分を含んだ機能性表示食品等が各社から販売されている。 Even when blood sugar levels rise after eating, insulin prevents excessive increases and keeps them within a certain range. However, when diabetes develops, the secretion and action of insulin are suppressed, making it difficult for blood sugar levels to return to normal, and it has been pointed out that there is a risk of developing complications such as arteriosclerosis due to hyperglycemia. It has also been pointed out that even if a person has not been diagnosed with diabetes, if their blood sugar levels rise sharply after meals or remain elevated for a long time, they may develop similar diseases. Such diabetes and hyperglycemia are often caused by poor diet and lack of exercise, and it is hoped that these conditions can be prevented and improved by reviewing lifestyle habits. Recently, with the aim of improving dietary habits, there has been progress in product development focusing on functional ingredients derived from safe, easy-to-consume foods, and various companies are selling functional food products containing ingredients that are particularly involved in suppressing blood sugar levels.
食品に由来する成分を利用した血糖値上昇抑制に関する技術としては、アミロース含量が３０質量％以上である米粒又は米粉を原料とし、レジスタントスターチ含量が０．４質量％以上かつ比重が０．５０ｇ／ｃｍ３以上１．００ｇ／ｃｍ３以下である血中インスリン濃度上昇抑制用米菓組成物であって、さらに血糖値上昇抑制に用いられる米菓組成物（特許文献１）、カカオポリフェノール及び脂質を有効成分として含んでなる、食後の血糖値上昇抑制用組成物（特許文献２）、茶花エキス、桑の葉エキス、及びキトサンを有効成分として含有する食後血糖値上昇抑制用組成物（特許文献３）等が開示されている。また、食品のなかでも、海藻に由来する成分を利用した技術としては、ラムナン硫酸を有効成分とし、ラムナン硫酸が緑藻類ヒトエグサ科ヒトエグサ属ヒトエグサより抽出したものである、血糖値上昇抑制剤（特許文献４）、アラメに由来する多糖類の加水分解物であって、かつ１００００Ｄａ～４６００００Ｄａの重量平均分子量を有する加水分解物を含む、糖尿病治療剤（特許文献５）等が開示されている。 Disclosed technologies relating to the suppression of increases in blood glucose levels using components derived from food include a rice snack composition for suppressing increases in blood insulin levels, which is made from rice grains or rice flour with an amylose content of 30% by mass or more, has a resistant starch content of 0.4% by mass or more , and has a specific gravity of 0.50 g/cm3 to 1.00 g/cm3, and is further used to suppress increases in blood glucose levels (Patent Document 1); a composition for suppressing increases in postprandial blood glucose levels, which contains cocoa polyphenols and lipids as active ingredients (Patent Document 2); and a composition for suppressing increases in postprandial blood glucose levels, which contains tea flower extract, mulberry leaf extract, and chitosan as active ingredients (Patent Document 3). Furthermore, among foods, technologies that utilize components derived from seaweed include a blood glucose level elevation inhibitor (Patent Document 4), which uses rhamnan sulfate as an active ingredient and is extracted from the green algae Streptomyces of the genus Streptomyces of the family Streptomyces (Streptomyces) (Patent Document 4), and a diabetes treatment agent that contains a hydrolysate of polysaccharides derived from Eisenia bicolor and has a weight-average molecular weight of 10,000 Da to 460,000 Da (Patent Document 5).
しかし、これらの技術をもってしても、血糖値上昇抑制に関する効果は必ずしも十分とはいえず、より実用性があり、広く一般に利用されやすい血糖値上昇抑制に関する技術が求められている。 However, even with these technologies, the effectiveness in suppressing blood sugar levels is not necessarily sufficient, and there is a demand for more practical technologies for suppressing blood sugar levels that are easily accessible to the general public.
本発明は、食後の血糖値の上昇を抑制する血糖値上昇抑制剤を提供することを目的とする。 The present invention aims to provide a blood glucose level increase inhibitor that suppresses the rise in blood glucose levels after meals.
本発明者は、前記課題に対して鋭意検討を行った結果、海藻のなかでも褐藻類中に含まれるナトリウムを多価金属で置換し、粉末状褐藻類中の多価金属含有量及びナトリウム含有量を所定量とした粉末状褐藻類によって、前記課題が解決されることを見出し、この知見に基づいて本発明を成すに至った。 As a result of extensive research into the above-mentioned problem, the inventors discovered that the above-mentioned problem could be solved by replacing the sodium contained in brown algae, a type of seaweed, with a polyvalent metal, thereby producing powdered brown algae with a specified polyvalent metal content and sodium content. This finding led to the development of the present invention.
すなわち、本発明は、粉末状褐藻類中に含まれる多価金属が２質量％以上、かつナトリウムが１．５質量％以下である粉末状褐藻類を有効成分とすることを特徴とする血糖値上昇抑制剤、から成っている。 That is, the present invention comprises a blood sugar level elevation inhibitor characterized by having, as an active ingredient, powdered brown algae containing 2% by mass or more of polyvalent metals and 1.5% by mass or less of sodium.
本発明の血糖値上昇抑制剤は、褐藻類中に含まれるナトリウムを多価金属で置換していない通常の粉末状褐藻類と比較し、食後の血糖値の上昇抑制効果に優れている。 The blood glucose level rise inhibitor of the present invention is superior in its effect of suppressing postprandial blood glucose level rise compared to ordinary powdered brown algae in which the sodium contained in the brown algae is not replaced with a polyvalent metal.
本発明の血糖値上昇抑制剤の原料として用いられる褐藻類は、特に制限はないが、例えば、わかめ、こんぶ、もずく、あかもく等を挙げることができ、このなかでもわかめが好ましい。わかめとしては、例えば、ワカメ、ヒロメ、アオワカメ等を挙げることができる。本発明の血糖値上昇抑制剤の原料として用いられる褐藻類の部位に特に制限はないが、例えば、わかめの場合、葉、茎、芽かぶ等を挙げることができ、このなかでも葉が好ましい。本発明の血糖値上昇抑制剤の原料として用いられる褐藻類の産地に特に制限はないが、例えば、日本産、韓国産、中国産等を挙げることができる。 The brown algae used as a raw material for the blood glucose level rise inhibitor of the present invention are not particularly limited, but examples include wakame, kelp, mozuku, and akame seaweed, with wakame being preferred. Examples of wakame include wakame, hirome, and aowakame. There are no particular restrictions on the part of brown algae used as a raw material for the blood glucose level rise inhibitor of the present invention, but in the case of wakame, examples include leaves, stems, and buds, with leaves being preferred. There are no particular restrictions on the origin of the brown algae used as a raw material for the blood glucose level rise inhibitor of the present invention, but examples include Japan, Korea, and China.
本発明の血糖値上昇抑制剤の原料として用いられる褐藻類は、生の褐藻類（原藻）、生の褐藻類をボイルしたもの、これらに冷蔵、冷凍、塩蔵、乾燥、カット等の加工処理を施したもの等を挙げることができ、このなかでも原藻、カット加工処理を施したものが好ましい。加工処理を施したものとしては、例えば、塩蔵わかめ、ボイル塩蔵わかめ、乾燥わかめ、カットわかめ等を挙げることができる。 The brown algae used as a raw material for the blood glucose level elevation inhibitor of the present invention include raw brown algae (raw algae), boiled raw brown algae, and processed products such as refrigeration, freezing, salting, drying, and cutting. Of these, raw algae and cut products are preferred. Examples of processed products include salted wakame, boiled salted wakame, dried wakame, and cut wakame.
ボイルわかめは、例えば、原藻を加温した海水等でボイルすることで得ることができ、これに食塩を添加し脱水させることでボイル塩蔵わかめを得ることができる。乾燥わかめは、例えば、ボイル塩蔵わかめを水で洗浄し、脱塩処理を施した後、自体公知の乾燥処理により得ることができる。 Boiled wakame can be obtained, for example, by boiling raw seaweed in heated seawater, and then adding salt and dehydrating it to obtain boiled salted wakame. Dried wakame can be obtained, for example, by washing boiled salted wakame with water, subjecting it to a desalting process, and then subjecting it to a drying process known per se.
本発明の血糖値上昇抑制剤の原料として用いられる褐藻類の大きさは、特に制限はないが、後述する多価金属イオンとの接触面積を広くする観点から、縦横それぞれ５０ｍｍ以下が好ましく、縦横それぞれ２０ｍｍ以下がより好ましい。本発明の血糖値上昇抑制剤の原料として用いられる褐藻類の形状は、特に制限はなく、多角形、不定形、粉末状等であってもよい。本発明では、褐藻類を１種のみ、又は任意の２種以上を組み合わせて用いることができる。 The size of the brown algae used as a raw material for the blood glucose level elevation inhibitor of the present invention is not particularly limited, but from the perspective of increasing the contact area with the polyvalent metal ions described below, it is preferably 50 mm or less in both length and width, and more preferably 20 mm or less in both length and width. The shape of the brown algae used as a raw material for the blood glucose level elevation inhibitor of the present invention is not particularly limited, and may be polygonal, irregular, powdery, etc. In the present invention, only one type of brown algae can be used, or any combination of two or more types can be used.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類は、粉末状褐藻類中に含まれる多価金属が２質量％以上であり、４質量％以上が好ましく、５質量％以上がより好ましく、６質量％以上がさらに好ましい。多価金属としては、例えば、２～３価の金属イオンを発生する金属を挙げることができ、具体的には、カルシウム、マグネシウム等の２族元素の金属を挙げることができ、好ましくはカルシウムである。 The powdered brown algae that is the active ingredient in the blood glucose level elevation inhibitor of the present invention contains a polyvalent metal in an amount of 2% by mass or more, preferably 4% by mass or more, more preferably 5% by mass or more, and even more preferably 6% by mass or more. Examples of polyvalent metals include metals that generate divalent or trivalent metal ions, specifically metals of Group 2 elements such as calcium and magnesium, with calcium being preferred.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類は、粉末状褐藻類中に含まれるナトリウムが１．５質量％以下であり、１質量％以下が好ましく、０．５質量％以下がより好ましく、０．３質量％以下がさらに好ましい。 The powdered brown algae that is the active ingredient in the blood glucose level elevation inhibitor of the present invention contains sodium in an amount of 1.5% by mass or less, preferably 1% by mass or less, more preferably 0.5% by mass or less, and even more preferably 0.3% by mass or less.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類中に含まれる多価金属とナトリウムの質量比（多価金属／ナトリウム）は、７以上が好ましく、１２以上がより好ましく、２５以上がさらに好ましい。本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類中に含まれるカルシウムとナトリウムの質量比（カルシウム／ナトリウム）は、５以上が好ましく、１０以上がより好ましく、２０以上がさらに好ましい。 The mass ratio of polyvalent metal to sodium (polyvalent metal/sodium) contained in the powdered brown algae, which is the active ingredient of the blood glucose level elevation inhibitor of the present invention, is preferably 7 or more, more preferably 12 or more, and even more preferably 25 or more. The mass ratio of calcium to sodium (calcium/sodium) contained in the powdered brown algae, which is the active ingredient of the blood glucose level elevation inhibitor of the present invention, is preferably 5 or more, more preferably 10 or more, and even more preferably 20 or more.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類中に含まれる多価金属含有量及びナトリウム含有量は、例えば、粉末状褐藻類に硝酸を加えマイクロ波試料前処理装置（型式：ＥＴＨＯＳ ＴＣ；マイルストーンゼネラル社製）で湿式分解後、ＩＣＰ発光分析装置（型式：ＶＩＳＴＡ－ＭＰＸ；ＶＡＲＩＡＮ社製）を用いて測定することができる。なお、粉末状褐藻類中に含まれるこれらの含有量を測定する際、粉末状褐藻類に食品素材等の他の成分が別途混合、或いは付着している場合は、これを洗浄等により除去した上で測定することができる。 The polyvalent metal and sodium contents contained in powdered brown algae, which is the active ingredient in the blood glucose level elevation inhibitor of the present invention, can be measured, for example, by adding nitric acid to the powdered brown algae, wet-digesting it using a microwave sample pretreatment device (model: ETHOS TC; manufactured by Milestone General), and then measuring it using an ICP optical emission analyzer (model: VISTA-MPX; manufactured by VARIAN). When measuring these contents in powdered brown algae, if other ingredients, such as food materials, are separately mixed with or attached to the powdered brown algae, these can be removed by washing or other methods before measurement.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類の水分含有量は、特に制限はないが、１０質量％以下が好ましく、５質量％以下がより好ましい。水分含有量は、例えば、常圧加熱乾燥法（１０５℃、３～５時間乾燥）により測定することができる。 The moisture content of powdered brown algae, which is the active ingredient in the blood glucose level elevation suppressant of the present invention, is not particularly limited, but is preferably 10% by mass or less, and more preferably 5% by mass or less. The moisture content can be measured, for example, by the atmospheric pressure heat drying method (drying at 105°C for 3 to 5 hours).
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類は、粉末状の形態であれば、粒子の大きさに特に制限はないが、例えば、目開き０．５ｍｍの篩を通過する大きさが好ましく、目開き０．３ｍｍの篩を通過する大きさがより好ましく、目開き０．２ｍｍの篩を通過する大きさがさらに好ましい。 The powdered brown algae that is the active ingredient in the blood glucose level elevation inhibitor of the present invention is not particularly limited in particle size as long as it is in powder form, but for example, a size that can pass through a sieve with a mesh size of 0.5 mm is preferred, a size that can pass through a sieve with a mesh size of 0.3 mm is more preferred, and a size that can pass through a sieve with a mesh size of 0.2 mm is even more preferred.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類は、少なくとも褐藻類と多価金属イオンとを接触処理する工程、多価金属イオンを接触処理させた褐藻類を洗浄する工程、洗浄された褐藻類を乾燥する工程を取ることで製造することができる。 The powdered brown algae that is the active ingredient in the blood glucose level elevation suppressant of the present invention can be produced by at least the steps of bringing brown algae into contact with polyvalent metal ions, washing the brown algae that has been contacted with the polyvalent metal ions, and drying the washed brown algae.
褐藻類と多価金属イオンとを接触処理する工程で用いられる多価金属イオンは、例えば、２～３価の金属イオンを挙げることができ、このなかでも２族元素のイオンが好ましく、カルシウムイオン、マグネシウムイオンがより好ましく、カルシウムイオンがさらに好ましい。多価金属イオンを発生する多価金属イオン源は、安全衛生上、食品に用いることができ、水等の溶媒に溶解するものであれば、特に制限はないが、カルシウム塩、マグネシウム塩等の多価金属塩等を挙げることができる。カルシウム塩としては、酢酸カルシウム、乳酸カルシウム、硝酸カルシウム、リン酸二水素カルシウム、グルコン酸カルシウム、塩化カルシウム及びこれらの水和物等を挙げることができる。マグネシウム塩としては、硫酸マグネシウム、塩化マグネシウム及びこれらの水和物等を挙げることができる。これら多価金属イオン源のなかでも、塩化カルシウム、塩化カルシウムの水和物、酢酸カルシウム、酢酸カルシウムの水和物、塩化マグネシウム、塩化マグネシウムの水和物が好ましく、塩化カルシウム、塩化カルシウムの水和物、酢酸カルシウム、酢酸カルシウムの水和物がより好ましい。本発明では、多価金属イオン及び多価金属イオン源を１種のみ、又は任意の２種以上を組み合わせて用いることができる。 The polyvalent metal ions used in the process of contacting brown algae with polyvalent metal ions include, for example, divalent and trivalent metal ions. Among these, ions of Group 2 elements are preferred, with calcium and magnesium ions being more preferred, and calcium ions being even more preferred. The polyvalent metal ion source that generates the polyvalent metal ions is not particularly limited as long as it is safe and hygienic for use in food and dissolves in a solvent such as water. Examples of polyvalent metal salts include calcium salts and magnesium salts. Examples of calcium salts include calcium acetate, calcium lactate, calcium nitrate, calcium dihydrogen phosphate, calcium gluconate, calcium chloride, and hydrates thereof. Examples of magnesium salts include magnesium sulfate, magnesium chloride, and hydrates thereof. Among these polyvalent metal ion sources, calcium chloride, calcium chloride hydrate, calcium acetate, calcium acetate hydrate, magnesium chloride, and magnesium chloride hydrate are preferred, with calcium chloride, calcium chloride hydrate, calcium acetate, and calcium acetate hydrate being more preferred. In the present invention, polyvalent metal ions and polyvalent metal ion sources can be used alone, or any combination of two or more types can be used.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類の製造方法における工程の１つである褐藻類と多価金属イオンとを接触処理する工程は、褐藻類中のナトリウムをカルシウムで置換できる方法であれば、特に制限はないが、例えば、多価金属イオン源を水等の溶媒に溶解した溶液に褐藻類を投入し浸漬する方法、褐藻類と水等の溶媒との混合物に多価金属イオン源を添加し浸漬する方法、褐藻類を充填した容器に多価金属イオン源を水等の溶媒に溶解した溶液を通液し浸漬する方法、原藻等の水分含有量の多い褐藻類に直接多価金属イオン源を添加する方法等を挙げることができる。前記した方法を行う際は、振とう、攪拌、混合等の操作をしてもよい。
本発明では、褐藻類と多価金属イオンとを接触処理させ、多価金属イオンを含む溶液を濾過、脱水等により除去した後、さらに褐藻類と多価金属イオンとを接触処理させることにより、複数回、褐藻類と多価金属イオンとを接触処理させることが好ましい。
The step of contacting brown algae with polyvalent metal ions, which is one of the steps in the method for producing powdered brown algae that is an active ingredient in the blood glucose level rise inhibitor of the present invention, is not particularly limited as long as it is a method that can replace sodium in the brown algae with calcium, but examples include a method in which brown algae are placed in a solution in which a polyvalent metal ion source is dissolved in a solvent such as water and then immersed, a method in which a polyvalent metal ion source is added to a mixture of brown algae and a solvent such as water and then immersed, a method in which a solution in which a polyvalent metal ion source is dissolved in a solvent such as water is passed through a container filled with brown algae and then immersed, and a method in which a polyvalent metal ion source is directly added to brown algae with a high water content, such as raw algae. When performing the above-mentioned methods, operations such as shaking, stirring, and mixing may be performed.
In the present invention, it is preferable to contact the brown algae with polyvalent metal ions multiple times by contacting the brown algae with polyvalent metal ions, removing the solution containing the polyvalent metal ions by filtration, dehydration, etc., and then contacting the brown algae with polyvalent metal ions again.
多価金属イオンを水等の溶媒を介して褐藻類と接触処理する場合、多価金属イオン源と水等の溶媒との溶液における多価金属イオン濃度は、特に制限はないが、０．０５質量％以上が好ましく、０．１質量％以上がより好ましく、０．３質量％以上がさらに好ましい。褐藻類と多価金属イオンとを接触処理する際の多価金属イオンと褐藻類の質量比（多価金属イオン／褐藻類）は、特に制限はないが、０．００５以上が好ましく、０．０１以上がより好ましく、０．０５以上がさらに好ましい。なお、多価金属イオン源と水等の溶媒との溶液における多価金属イオン濃度は、溶媒の質量をＡ、多価金属イオン源の質量をＢ、多価金属イオン源１モルあたりの質量をＭ、多価金属イオン源１モル中の多価金属の質量をｍとすると、下記式によって算出することができる。 When polyvalent metal ions are contacted with brown algae via a solvent such as water, the polyvalent metal ion concentration in the solution of the polyvalent metal ion source and water or other solvent is not particularly limited, but is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.3% by mass or more. The mass ratio of polyvalent metal ions to brown algae (polyvalent metal ions/brown algae) when contacting brown algae with polyvalent metal ions is not particularly limited, but is preferably 0.005 or more, more preferably 0.01 or more, and even more preferably 0.05 or more. The polyvalent metal ion concentration in the solution of the polyvalent metal ion source and water or other solvent can be calculated using the following formula, where A is the mass of the solvent, B is the mass of the polyvalent metal ion source, M is the mass per mole of the polyvalent metal ion source, and m is the mass of the polyvalent metal in 1 mole of the polyvalent metal ion source.
多価金属イオン濃度（質量％）＝Ｂ×（ｍ／Ｍ）×１００／（Ａ＋Ｂ） Polyvalent metal ion concentration (mass%) = B x (m/M) x 100 / (A + B)
褐藻類と多価金属イオンとを接触処理する時間は、特に制限はないが、１０分以上が好ましく、３０分以上がより好ましく、６０分以上がさらに好ましい。褐藻類と多価金属イオンとを接触処理する際の温度は、特に制限はないが、室温（２５±５℃）以上が好ましく、５０℃以上がより好ましく、７０℃以上がさらに好ましい。 There are no particular restrictions on the time for which brown algae are brought into contact with polyvalent metal ions, but 10 minutes or more is preferred, 30 minutes or more is more preferred, and 60 minutes or more is even more preferred. There are no particular restrictions on the temperature for which brown algae are brought into contact with polyvalent metal ions, but a temperature of room temperature (25±5°C) or higher is preferred, 50°C or higher is more preferred, and 70°C or higher is even more preferred.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類の製造方法における工程の１つである多価金属イオンを接触処理させた褐藻類を洗浄する工程は、褐藻類と多価金属イオンとを接触処理する工程で用いた多価金属イオンを含む溶液を濾過、脱水等により除去した褐藻類（以下、処理済み褐藻類ともいう）に付着している余分な多価金属イオンや食塩、褐藻類と多価金属イオンとを接触処理する工程で生成したナトリウム塩等を洗浄液により十分に洗い流すことができれば、特に制限はないが、例えば、洗浄液に処理済み褐藻類を投入し浸漬する方法、処理済み褐藻類を充填した容器に洗浄液を通液し浸漬する方法等を挙げることができ、浸漬する際に、振とう、攪拌、混合等の操作をしてもよい。本発明では、処理済み褐藻類の洗浄後、洗浄液を濾過、脱水等により除去した後、さらに洗浄工程を取ることで、複数回、処理済み褐藻類を洗浄することが好ましい。また、十分な洗浄の目安として、濾過、脱水等により除去した最後の洗浄液中のナトリウム濃度を測定してもよい。この場合、ナトリウム濃度は、０．００５質量％未満が好ましい。洗浄液は、特に制限はないが、水、エタノール等のアルコール類を挙げることができ、このなかでも水が好ましい。 The process of washing brown algae that has been contact-treated with polyvalent metal ions, which is one of the steps in the method for producing powdered brown algae that is an active ingredient in the blood glucose level elevation inhibitor of the present invention, is not particularly limited as long as the washing solution can thoroughly wash away excess polyvalent metal ions and salt adhering to the brown algae (hereinafter referred to as "treated brown algae"), as well as sodium salts generated during the contact-treatment process, after the polyvalent metal ion-containing solution used in the contact-treatment process has been removed by filtration, dehydration, etc., from the brown algae. Examples of such methods include placing the treated brown algae in a washing solution and immersing them, or passing the washing solution through a container filled with the treated brown algae and immersing them. During immersion, the treated brown algae may be shaken, stirred, mixed, or otherwise treated. In the present invention, after washing the treated brown algae, the washing solution is removed by filtration, dehydration, etc., and then a further washing step is performed, thereby washing the treated brown algae multiple times. As a measure of sufficient cleaning, the sodium concentration in the final cleaning solution removed by filtration, dehydration, etc. may be measured. In this case, the sodium concentration is preferably less than 0.005% by mass. There are no particular restrictions on the cleaning solution, but examples include water and alcohols such as ethanol, with water being preferred.
多価金属イオンを接触処理させた褐藻類を洗浄する際の洗浄液と処理済み褐藻類の質量比（洗浄液／処理済み褐藻類）は、特に制限はないが、４以上が好ましく、１０以上がより好ましい。多価金属イオンを接触処理させた褐藻類を洗浄する時間は、特に制限はないが、１分以上が好ましく、５分以上がより好ましく、１０分以上がさらに好ましい。 When washing brown algae that have been contact-treated with polyvalent metal ions, the mass ratio of the washing solution to the treated brown algae (washing solution/treated brown algae) is not particularly limited, but is preferably 4 or more, and more preferably 10 or more. There is no particular limit to the time for washing brown algae that have been contact-treated with polyvalent metal ions, but is preferably 1 minute or more, more preferably 5 minutes or more, and even more preferably 10 minutes or more.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類の製造方法における工程の１つである洗浄された褐藻類を乾燥する工程は、洗浄工程を経た処理済み褐藻類を乾燥することができれば、特に制限はないが、例えば、自然乾燥、熱風乾燥、凍結乾燥、真空乾燥等の方法を挙げることができ、１種のみ、又は任意の２種以上を組み合わせて用いてもよい。乾燥工程における条件は、例えば、熱風乾燥の場合、８０～１００℃、１～５時間が好ましく、真空乾燥の場合、６０～８０℃、３～２０時間が好ましい。 The drying step of washed brown algae, which is one of the steps in the method for producing powdered brown algae, an active ingredient in the blood glucose level elevation inhibitor of the present invention, is not particularly limited as long as it can dry the treated brown algae that have undergone the washing step. Examples of suitable methods include natural drying, hot air drying, freeze drying, and vacuum drying, and these methods may be used alone or in combination with any two or more of them. For example, the drying conditions are preferably 80-100°C for 1-5 hours for hot air drying, and 60-80°C for 3-20 hours for vacuum drying.
本発明の血糖値上昇抑制剤の有効成分である粉末状褐藻類の製造方法では、粉末化工程を取ることもできる。粉末化工程は、特に制限はないが、ピンミル粉砕、気流式粉砕、剪断摩擦式粉砕、衝撃式粉砕、ロール式粉砕、凍結粉砕、超音波粉砕、超遠心粉砕等を挙げることができ、１種のみ、又は任意の２種以上を組み合わせて用いてもよい。 The method for producing powdered brown algae, which is an active ingredient in the blood glucose level elevation inhibitor of the present invention, can also include a powdering step. The powdering step is not particularly limited, but examples include pin mill grinding, airflow grinding, shear friction grinding, impact grinding, roll grinding, freeze grinding, ultrasonic grinding, and ultracentrifugal grinding, and these may be used alone or in combination of any two or more types.
本発明の血糖値上昇抑制剤は、有効成分である粉末状褐藻類のみをそのまま用いてもよく、有効成分である粉末状褐藻類以外に、本発明の効果を阻害しない範囲で、他の任意の成分を混合し製剤として調整したものでもよい。製剤として調整する場合、製剤中における有効成分である粉末状褐藻類の含有量に特に制限はないが、好ましくは１質量％以上、より好ましくは１０質量％以上である。 The blood glucose level elevation inhibitor of the present invention may use only the powdered brown algae as the active ingredient, or may be prepared as a formulation by mixing other optional ingredients in addition to the powdered brown algae as the active ingredient, as long as the effects of the present invention are not impaired. When prepared as a formulation, there are no particular restrictions on the content of the powdered brown algae as the active ingredient in the formulation, but it is preferably 1% by mass or more, and more preferably 10% by mass or more.
前記した他の任意の成分としては、例えば、分岐デキストリン、環状デキストリン、難消化性デキストリン等のデキストリン、寒天、ゼラチン、ペクチン、カラギナン、マンナン、大豆多糖類、キサンタンガム、ローカストビーンガム、グアーガム、アラビアガム等の安定剤、ソルビトール、マルチトール、エリスリトール、キシリトール等の糖アルコール、アスパルテーム、アセスルファムカリウム等の甘味料、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル等の乳化剤、カゼインナトリウム、リン酸塩、セルロース等の賦形剤等を挙げることができる。 Examples of the other optional ingredients mentioned above include dextrins such as branched dextrin, cyclic dextrin, and indigestible dextrin; stabilizers such as agar, gelatin, pectin, carrageenan, mannan, soybean polysaccharides, xanthan gum, locust bean gum, guar gum, and gum arabic; sugar alcohols such as sorbitol, maltitol, erythritol, and xylitol; sweeteners such as aspartame and acesulfame potassium; emulsifiers such as glycerin fatty acid esters and sucrose fatty acid esters; and excipients such as sodium caseinate, phosphates, and cellulose.
本発明の血糖値上昇抑制剤の使用方法は、ヒトに経口的に摂取できる方法であれば特に制限はなく、本発明の血糖値上昇抑制剤を直接又は飲食品に添加して摂取することができる。本発明の血糖値上昇抑制剤は、食事の６０分前までに摂取することが好ましく、食事の３０分前までに摂取することがより好ましく、食事と同時に摂取することがさらに好ましい。本発明の血糖値上昇抑制剤の使用量は、一回の食事に対して、有効成分である粉末状褐藻類が好ましくは０．１ｇ以上、より好ましくは０．５ｇ以上、さらに好ましくは１ｇ以上となるよう摂取するのがよい。摂取する上限に特に制限はないが、一回の食事に対して、有効成分である粉末状褐藻類が１０ｇ以下となるよう摂取することが好ましい。 There are no particular limitations on the method of use for the blood glucose level rise inhibitor of the present invention, as long as it can be taken orally by humans. The blood glucose level rise inhibitor of the present invention can be taken directly or by adding it to food and beverages. The blood glucose level rise inhibitor of the present invention is preferably taken up to 60 minutes before a meal, more preferably up to 30 minutes before a meal, and even more preferably taken at the same time as a meal. The amount of the blood glucose level rise inhibitor of the present invention to be used is preferably 0.1 g or more, more preferably 0.5 g or more, and even more preferably 1 g or more of powdered brown algae as the active ingredient per meal. There is no particular upper limit on the amount to be taken, but it is preferable to take 10 g or less of powdered brown algae as the active ingredient per meal.
本発明の血糖値上昇抑制剤の飲食品への添加量に特に制限はないが、飲食品中に粉末状褐藻類が好ましくは０．１～１００質量％、より好ましくは１～１００質量％含有させるのがよい。 There are no particular restrictions on the amount of the blood glucose level elevation inhibitor of the present invention that can be added to food or beverages, but it is preferable for the powdered brown algae to be contained in the food or beverage in an amount of preferably 0.1 to 100% by mass, and more preferably 1 to 100% by mass.
本発明の血糖値上昇抑制剤を添加できる飲食品は、特に制限はないが、例えば、パン、菓子、麺、米飯、豆腐、水産練り製品、飲料、乳製品、スープ、調味料、プレミックス、介護食等の一般食品の他、健康食品等を挙げることができる。パンは、食パン、菓子パン、デニッシュ、ペストリー、クロワッサン、ブリオッシュ、フランスパン等を挙げることができる。菓子は、ガム、キャンディ、グミ、チョコレート、クッキー、ビスケット、ケーキ、パンケーキ、カステラ、バームクーヘン、ドーナツ、スティックバー、スナック菓子、米菓、氷菓、アイスクリーム等を挙げることができる。麺は、中華麺、うどん、そば、そうめん、パスタ、餃子の皮等を挙げることができ、生麺の他、茹で麺、蒸し麺、即席麺、冷蔵麺、冷凍麺等の調理済みの麺も含まれる。米飯は、炊き込みご飯、ピラフ、ドライカレー、リゾット等を挙げることができる。水産練り製品は、かまぼこ、ちくわ、はんぺん、つみれ、さつま揚げ等を挙げることができる。飲料は、茶、コーヒー、インスタントコーヒー、果汁飲料、野菜飲料、炭酸飲料、スポーツ飲料、粉末スポーツ飲料、乳飲料、乳酸菌飲料、栄養ドリンク、青汁、粉末青汁等を挙げることができ、固形状、粉末状、ペースト状、液状等のいずれの形態であってもよい。 The foods and beverages to which the blood glucose level elevation inhibitor of the present invention can be added are not particularly limited, and examples include general foods such as bread, confectionery, noodles, cooked rice, tofu, fish paste products, beverages, dairy products, soups, seasonings, premixes, and nursing care foods, as well as health foods. Examples of bread include white bread, sweet rolls, Danish pastries, pastries, croissants, brioche, and French baguettes. Examples of sweets include gum, candy, gummy candies, chocolate, cookies, biscuits, cakes, pancakes, castella cakes, Baumkuchen, donuts, stick bars, snacks, rice crackers, frozen desserts, and ice cream. Examples of noodles include Chinese noodles, udon, soba, somen, pasta, and gyoza wrappers, including fresh noodles as well as cooked noodles such as boiled noodles, steamed noodles, instant noodles, refrigerated noodles, and frozen noodles. Examples of cooked rice include seasoned rice, pilaf, dry curry, and risotto. Examples of fish paste products include kamaboko, chikuwa, hanpen, tsumire, satsumaage, etc. Examples of beverages include tea, coffee, instant coffee, fruit juice drinks, vegetable drinks, carbonated drinks, sports drinks, powdered sports drinks, milk drinks, lactic acid bacteria drinks, nutritional drinks, green juice, and powdered green juice, and they may be in any form, such as solid, powder, paste, or liquid.
乳製品は、ヨーグルト、クリーム、チーズ、バター、粉乳、練乳等を挙げることができる。スープは、コーンスープ、コンソメスープ、中華スープ、ラーメンスープ、オニオンスープ、ミネストローネ、クラムチャウダー、ポタージュ、わかめスープ、味噌汁等を挙げることができ、固形状、粉末状、ペースト状、ゼリー状、ジュレ状、液状等のいずれの形態であってもよい。調味料は、醤油、味噌、ソース、たれ、つゆ、魚醤、エキス、ドレッシング、シーズニング等を挙げることができ、固形状、粉末状、ペースト状、ゼリー状、ジュレ状、液状等のいずれの形態であってもよい。プレミックスは、原料の一部があらかじめ混合された食品をいい、パン用プレミックス、ケーキ用プレミックス、パンケーキ用プレミックス、アイスクリーム用プレミックス、麺用プレミックス等を挙げることができる。健康食品は、栄養機能食品、栄養補助食品、健康補助食品、機能性食品、機能性表示食品、特定保健用食品、サプリメント、流動食等を挙げることができ、錠剤、カプセル、固形状、粉末状、ペースト状、ゼリー状、ジュレ状、液状等のいずれの形態であってもよい。 Examples of dairy products include yogurt, cream, cheese, butter, powdered milk, and condensed milk. Examples of soups include corn soup, consommé soup, Chinese soup, ramen soup, onion soup, minestrone, clam chowder, potage, seaweed soup, and miso soup, and may be in any form, such as solid, powder, paste, jelly, gelee, or liquid. Examples of seasonings include soy sauce, miso, sauce, dipping sauce, fish sauce, extract, dressing, and seasoning, and may be in any form, such as solid, powder, paste, jelly, gelee, or liquid. Premixes refer to foods in which some of the ingredients are premixed, and examples include bread premixes, cake premixes, pancake premixes, ice cream premixes, and noodle premixes. Examples of health foods include functional nutritional foods, nutritional supplements, health supplements, functional foods, foods with functional claims, foods for specified health uses, supplements, and liquid foods, and may be in any form such as tablets, capsules, solids, powders, pastes, jellies, gelees, or liquids.
以下、実施例をもって本発明を具体的に説明するが、本発明はこれらに制限されるものではない。 The present invention will be explained in detail below using examples, but the present invention is not limited to these.
［血糖値上昇抑制剤の作製］
（１）血糖値上昇抑制剤の作製方法
１）実施例１
２Ｌステンレスビーカーに水９００ｇ、酢酸カルシウム一水和物（商品名：カルフレッシュ；大東化学社製）１４．４ｇを投入し、６５℃で３分間攪拌し、多価金属イオン溶液（カルシウムイオン濃度：０．３５質量％）を得た。この溶液に韓国産乾燥わかめ６０ｇを投入後、６５～７０℃で２０分間攪拌した後、濾過にて溶液を除去することで、１次処理済み褐藻類２１６ｇを得た。次に、２Ｌステンレスビーカーで水９００ｇに酢酸カルシウム一水和物（商品名：カルフレッシュ；大東化学社製）３．６ｇを溶解した多価金属イオン溶液（カルシウムイオン濃度：０．０９質量％）に１次処理済み褐藻類全量を投入後、６５～７０℃で２０分間攪拌した後、濾過にて溶液を除去することで、２次処理済み褐藻類１８９ｇを得た。次に、２Ｌステンレスビーカーに２次処理済み褐藻類全量、洗浄液として水９００ｇを投入後、室温で３分間攪拌して洗浄し、濾過にて洗浄液を除去した。さらに、同様の洗浄操作を１回行った。この際除去した洗浄液中のナトリウム濃度を測定したところ０．００５質量％未満であり、十分に洗浄できていることを確認できた。洗浄液を除去した処理済み褐藻類を熱風乾燥機（テスト用乾燥炉；細山熱器社製）で、９０℃、２時間乾燥した後、超遠心粉砕機（型式：ＺＭ２００；ＲＥＴＳＣＨ社製）で、１４０００ｒｐｍ、スクリーン目開き０．２ｍｍの条件で粉砕し、粉末状褐藻類Ａを４４．６ｇ得た。粉末状褐藻類Ａの水分含有量は４．２質量％であった。粉末状褐藻類Ａをそのまま血糖値上昇抑制剤Ａとした。
[Preparation of blood glucose level increase inhibitor]
(1) Method for Producing an Agent for Suppressing Blood Glucose Level Increase 1) Example 1
900 g of water and 14.4 g of calcium acetate monohydrate (trade name: Calcfresh; manufactured by Daito Chemical Co., Ltd.) were added to a 2 L stainless steel beaker and stirred at 65 ° C. for 3 minutes to obtain a polyvalent metal ion solution (calcium ion concentration: 0.35% by mass). 60 g of dried Korean wakame seaweed was added to this solution, and the solution was then stirred at 65 to 70 ° C. for 20 minutes, after which the solution was removed by filtration to obtain 216 g of primary-treated brown algae. Next, in a 2 L stainless steel beaker, 3.6 g of calcium acetate monohydrate (trade name: Calcfresh; manufactured by Daito Chemical Co., Ltd.) was dissolved in 900 g of water. The entire amount of primary-treated brown algae was added to a polyvalent metal ion solution (calcium ion concentration: 0.09% by mass), and the mixture was stirred at 65 to 70 ° C. for 20 minutes, after which the solution was removed by filtration to obtain 189 g of secondary-treated brown algae. Next, the entire amount of secondary-treated brown algae and 900 g of water as a washing solution were added to a 2 L stainless steel beaker, and the mixture was washed by stirring at room temperature for 3 minutes, and the washing solution was removed by filtration. Furthermore, the same washing operation was performed once. The sodium concentration in the removed washing solution was measured and found to be less than 0.005% by mass, confirming that the washing solution had been sufficiently removed. The treated brown algae from which the washing solution had been removed were dried at 90 ° C for 2 hours in a hot air dryer (test drying oven; manufactured by Hosoyama Netsuki Co., Ltd.), and then pulverized in an ultracentrifugal grinder (model: ZM200; manufactured by RETSCH) at 14,000 rpm with a screen opening of 0.2 mm to obtain 44.6 g of powdered brown algae A. The moisture content of the powdered brown algae A was 4.2% by mass. The powdered brown algae A was used as blood glucose level rise inhibitor A as is.
２）比較例１
韓国産乾燥わかめ２０ｇを超遠心粉砕機（型式：ＺＭ２００；ＲＥＴＳＣＨ社製）で、１４０００ｒｐｍ、スクリーン目開き０．２ｍｍの条件で粉砕し、粉末状褐藻類Ｂを１９．４ｇ得た。粉末状褐藻類Ｂの水分含有量は４．８質量％であった。粉末状褐藻類Ｂをそのまま血糖値上昇抑制剤Ｂとした。
2) Comparative Example 1
20 g of dried Korean wakame seaweed was pulverized in an ultracentrifugal pulverizer (model: ZM200; manufactured by RETSCH) at 14,000 rpm with a screen opening of 0.2 mm to obtain 19.4 g of powdered brown algae B. The water content of the powdered brown algae B was 4.8% by mass. The powdered brown algae B was used as blood glucose level elevation inhibitor B as is.
［粉末状褐藻類中に含まれる多価金属、ナトリウムの測定］
（１）多価金属含有量、ナトリウム含有量の測定
粉末状褐藻類Ａ、Ｂそれぞれについて、硝酸を加えマイクロ波試料前処理装置（型式：ＥＴＨＯＳ ＴＣ；マイルストーンゼネラル社製）で湿式分解後、ＩＣＰ発光分析装置（型式：ＶＩＳＴＡ－ＭＰＸ；ＶＡＲＩＡＮ社製）を用いて、多価金属含有量（カルシウム含有量、マグネシウム含有量）及びナトリウム含有量を測定した。結果を表１に示す。
[Measurement of polyvalent metals and sodium contained in powdered brown algae]
(1) Measurement of polyvalent metal content and sodium content For each of powdered brown algae A and B, nitric acid was added and wet decomposed using a microwave sample pretreatment device (model: ETHOS TC; manufactured by Milestone General Co., Ltd.). Then, the polyvalent metal content (calcium content, magnesium content) and sodium content were measured using an ICP optical emission analyzer (model: VISTA-MPX; manufactured by VARIAN Co., Ltd.). The results are shown in Table 1.
［血糖値上昇抑制試験１］
（１）試験方法
１）試験１（血糖値上昇抑制剤Ａ摂取区）
１２時間絶食した被験者に４０ｍｌの水を摂取させた後、インスタント味噌汁（商品名：いつものおみそ汁赤だし 三つ葉入り；アマノフーズ社製）１袋に熱湯１６０ｍｌと血糖値上昇抑制剤Ａ２ｇを混合したもの、及び白米（商品名：サトウのごはん 国内産コシヒカリ２００ｇ；サトウ食品社製）６５ｇを４０回程度の咀嚼とともに７分程度かけて摂取させた。摂取直後（０分後）、摂取３０分後、摂取４５分後、摂取６０分後、摂取７５分後に採血し、それぞれ血糖値を測定した。
[Blood glucose level increase suppression test 1]
(1) Test Method 1) Test 1 (Administered group of blood glucose level increase inhibitor A)
After fasting for 12 hours, subjects ingested 40 ml of water, then ingested one packet of instant miso soup (product name: Itsumo no Omiso Soup Akadashi with Mitsuba; manufactured by Amano Foods) mixed with 160 ml of hot water and 2 g of blood glucose level rise inhibitor A, and 65 g of white rice (product name: Sato no Gohan Domestic Koshihikari 200 g; manufactured by Sato Foods) over a period of approximately 7 minutes, chewing approximately 40 times. Blood was drawn immediately after ingestion (0 minutes), 30 minutes, 45 minutes, 60 minutes, and 75 minutes after ingestion, and blood glucose levels were measured.
２）試験２（血糖値上昇抑制剤Ｂ摂取区）
血糖値上昇抑制剤Ａを血糖値上昇抑制剤Ｂに変更すること以外は、試験１と同様の方法で、血糖値を測定した。
2) Test 2 (administration of blood glucose level increase inhibitor B)
Blood glucose levels were measured in the same manner as in Test 1, except that blood glucose level increase inhibitor A was replaced with blood glucose level increase inhibitor B.
３）試験３（対照区）
血糖値上昇抑制剤Ａ２ｇを摂取しないこと以外は、試験１と同様の方法で、血糖値を測定した。
3) Test 3 (control group)
Blood glucose levels were measured in the same manner as in Test 1, except that 2 g of blood glucose level increase inhibitor A was not taken.
４）試験４（参考例）
血糖値上昇抑制剤Ａを国産乾燥わかめに変更すること以外は、試験１と同様の方法で、血糖値を測定した。
4) Test 4 (reference example)
Blood glucose levels were measured in the same manner as in Test 1, except that blood glucose level increase inhibitor A was changed to domestically produced dried wakame seaweed.
試験１～４について、それぞれ摂取３０分後、摂取４５分後、摂取６０分後、摂取７５分後の血糖値と摂取直後（０分後）の血糖値との差である血糖値の上昇値（Δ値）（ｍｇ／ｄｌ）を求めた。結果を表２に示す。また、この結果をグラフ化し、図１に示す。 For Tests 1 to 4, the blood glucose rise (Δ value) (mg/dl) was calculated, which is the difference between the blood glucose levels 30 minutes, 45 minutes, 60 minutes, and 75 minutes after ingestion and the blood glucose level immediately after ingestion (0 minutes). The results are shown in Table 2. The results were also graphed and shown in Figure 1.
表２及び図１のとおり、摂取３０分後において、実施例である血糖値上昇抑制剤Ａを摂取した場合は、対照区及び比較例である血糖値上昇抑制剤Ｂを摂取した場合よりも、血糖値の上昇が顕著に抑制されていることがわかった。また、血糖値上昇抑制剤Ａを摂取した場合の血糖値の上昇値のピークは、対照区及び血糖値上昇抑制剤Ｂを摂取した場合の血糖値の上昇値のピークよりも低いことがわかった。 As shown in Table 2 and Figure 1, 30 minutes after ingestion, when blood glucose level rise inhibitor A of the example was ingested, blood glucose level rise was suppressed more significantly than when the control group and blood glucose level rise inhibitor B of the comparative example were ingested. It was also found that the peak blood glucose level rise when blood glucose level rise inhibitor A was ingested was lower than the peak blood glucose level rise when the control group and blood glucose level rise inhibitor B were ingested.
［血糖値上昇抑制試験２］
（１）試験方法
１）試験１（血糖値上昇抑制剤Ａ摂取区）
１２時間絶食した被験者に４０ｍｌの水を摂取させた後、白米（商品名：サトウのごはん 国内産コシヒカリ２００ｇ；サトウ食品社製）１１６ｇにカレー（商品名：小さめカレー 辛くない国産りんごと野菜のカレー；良品計画社製）１袋と血糖値上昇抑制剤Ａ１．５ｇを混合したものを、水１００ｍｌを飲みながら４０回程度の咀嚼とともに１０分程度かけて摂取させた。摂取直後（０分後）、摂取３０分後、摂取４５分後、摂取６０分後、摂取９０分後、摂取１２０分後に採血し、それぞれ血糖値を測定した。
[Blood glucose level increase suppression test 2]
(1) Test Method 1) Test 1 (Administered group of blood glucose level increase inhibitor A)
After fasting for 12 hours, subjects ingested 40 ml of water, and then ingested 116 g of white rice (product name: Sato's Rice, 200 g of domestically produced Koshihikari rice; manufactured by Sato Foods Co., Ltd.) mixed with one packet of curry (product name: Small Curry, mild domestic apple and vegetable curry; manufactured by Ryohin Keikaku Co., Ltd.) and 1.5 g of blood glucose level rise inhibitor A over a period of approximately 10 minutes while drinking 100 ml of water and chewing approximately 40 times. Blood samples were taken immediately after ingestion (0 minutes), 30 minutes, 45 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion, and blood glucose levels were measured.
２）試験２（血糖値上昇抑制剤Ｂ摂取区）
血糖値上昇抑制剤Ａを血糖値上昇抑制剤Ｂに変更すること以外は、試験１と同様の方法で、血糖値を測定した。
2) Test 2 (administration of blood glucose level increase inhibitor B)
Blood glucose levels were measured in the same manner as in Test 1, except that blood glucose level increase inhibitor A was replaced with blood glucose level increase inhibitor B.
３）試験３（対照区）
血糖値上昇抑制剤Ａ１．５ｇを摂取しないこと以外は、試験１と同様の方法で、血糖値を測定した。
3) Test 3 (control group)
Blood glucose levels were measured in the same manner as in Test 1, except that 1.5 g of blood glucose level increase inhibitor A was not taken.
試験１～３について、それぞれ摂取３０分後、摂取４５分後、摂取６０分後、摂取９０分後、摂取１２０分後の血糖値と摂取直後（０分後）の血糖値の差である血糖値の上昇値（Δ値）（ｍｇ／ｄｌ）を求めた。結果を表３に示す。また、この結果をグラフ化し、図２に示す。 For Tests 1 to 3, the blood glucose rise (Δ value) (mg/dl) was calculated, which is the difference between the blood glucose levels 30 minutes, 45 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion and the blood glucose level immediately after ingestion (0 minutes). The results are shown in Table 3. The results were also graphed and shown in Figure 2.
表３及び図２のとおり、摂取３０分後から摂取９０分後において、実施例である血糖値上昇抑制剤Ａを摂取した場合は、対照区及び比較例である血糖値上昇抑制剤Ｂを摂取した場合よりも、血糖値の上昇が顕著に抑制されていることがわかった。また、血糖値上昇抑制剤Ａを摂取した場合の血糖値の上昇値のピークは、対照区及び血糖値上昇抑制剤Ｂを摂取した場合の血糖値の上昇値のピークよりも低いことがわかった。 As shown in Table 3 and Figure 2, when blood glucose level rise inhibitor A of the example was taken, blood glucose level rise was suppressed more significantly between 30 and 90 minutes after ingestion than when the control group and blood glucose level rise inhibitor B of the comparative example were taken. Furthermore, it was found that the peak blood glucose level rise when blood glucose level rise inhibitor A was taken was lower than the peak blood glucose level rise when the control group and blood glucose level rise inhibitor B were taken.
［血糖値上昇抑制試験３］
（１）試験方法
１）試験１（血糖値上昇抑制剤Ａ摂取区）
１２時間絶食した被験者に４０ｍｌの水を摂取させた後、食事の直前に水１００ｍｌに血糖値上昇抑制剤Ａ１ｇを混合したものを摂取させ、次に白米（商品名：サトウのごはん 国内産コシヒカリ２００ｇ；サトウ食品社製）６５ｇを４０回程度の咀嚼とともに５分程度かけて摂取させた。摂取直後（０分後）、摂取３０分後に採血し、それぞれ血糖値を測定した。
[Blood glucose level increase suppression test 3]
(1) Test Method 1) Test 1 (Administered group of blood glucose level increase inhibitor A)
After fasting for 12 hours, subjects ingested 40 ml of water, and then immediately before a meal, they ingested 100 ml of water mixed with 1 g of blood glucose level rise inhibitor A, followed by 65 g of white rice (product name: Sato no Gohan Domestic Koshihikari 200 g; Sato Foods Co., Ltd.) over a period of about 5 minutes, chewing about 40 times. Blood was drawn immediately after ingestion (0 minutes) and 30 minutes after ingestion, and blood glucose levels were measured.
２）試験２（血糖値上昇抑制剤Ａ摂取区）
血糖値上昇抑制剤Ａ１ｇを血糖値上昇抑制剤Ａ２ｇに変更すること以外は、試験１と同様の方法で、血糖値を測定した。
2) Test 2 (administration of blood glucose level increase inhibitor A)
Blood glucose levels were measured in the same manner as in Test 1, except that 1 g of the blood glucose level increase inhibitor A was changed to 2 g of the blood glucose level increase inhibitor A.
３）試験３（対照区）
血糖値上昇抑制剤Ａ１ｇを摂取しないこと以外は、試験１と同様の方法で、血糖値を測定した。
3) Test 3 (control group)
Blood glucose levels were measured in the same manner as in Test 1, except that 1 g of blood glucose level increase inhibitor A was not taken.
試験１～３について、それぞれ摂取３０分後の血糖値と摂取直後（０分後）の血糖値の差である血糖値の上昇値（Δ値）（ｍｇ／ｄｌ）を求めた。結果を表４に示す。 For each of the tests 1 to 3, the increase in blood glucose level (Δ value) (mg/dl), which is the difference between the blood glucose level 30 minutes after ingestion and the blood glucose level immediately after ingestion (0 minutes after ingestion), was calculated. The results are shown in Table 4.
表４のとおり、実施例である血糖値上昇抑制剤Ａを多く摂取した方が、血糖値の上昇抑制効果が高いことがわかった。 As shown in Table 4, it was found that the greater the intake of the example blood glucose level elevation inhibitor A, the greater the effect of inhibiting blood glucose level elevation.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021107773A JP7744764B2 (en) | 2021-06-29 | 2021-06-29 | Blood sugar level suppressant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021107773A JP7744764B2 (en) | 2021-06-29 | 2021-06-29 | Blood sugar level suppressant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023005692A JP2023005692A (en) | 2023-01-18 |
| JP7744764B2 true JP7744764B2 (en) | 2025-09-26 |
Family
ID=85107643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021107773A Active JP7744764B2 (en) | 2021-06-29 | 2021-06-29 | Blood sugar level suppressant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7744764B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022140A1 (en) | 2000-09-13 | 2002-03-21 | Takara Bio Inc. | Homeostasis-maintaining agents |
| WO2005056035A1 (en) | 2003-12-10 | 2005-06-23 | Riken Vitamin Co., Ltd. | Alga extract and sugar hydrolase inhibitor containing the same |
| JP2018126126A (en) | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990011834A (en) * | 1997-07-25 | 1999-02-18 | 엠. 길 로렌스 | Blood glucose lowering composition and method for treating diabetes using same |
| JP2017095403A (en) * | 2015-11-25 | 2017-06-01 | 株式会社キミカ | Neutral fat lowering drug, weight gain inhibiting drug, excretion increasing drug, food and drink, feed and medicine |
| EP3235510A1 (en) * | 2016-04-18 | 2017-10-25 | Dialpha | Nutritional compositions for the management of glucose metabolism |
-
2021
- 2021-06-29 JP JP2021107773A patent/JP7744764B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022140A1 (en) | 2000-09-13 | 2002-03-21 | Takara Bio Inc. | Homeostasis-maintaining agents |
| WO2005056035A1 (en) | 2003-12-10 | 2005-06-23 | Riken Vitamin Co., Ltd. | Alga extract and sugar hydrolase inhibitor containing the same |
| JP2018126126A (en) | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023005692A (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100551254C (en) | Sweet Potato Jam and Its Making Technology | |
| RU2662770C2 (en) | Flavour composition and edible compositions containing same | |
| JP3772833B2 (en) | Water-soluble dietary fiber derived from cacao husk and method for producing the same, food and drink using the fiber, and method for producing the same | |
| JPH05255402A (en) | Slightly digestible dextrin | |
| JP4448266B2 (en) | Chillability improving agent and composition for improving cooling performance | |
| WO2014077019A1 (en) | Sweetness and/or milk flavor enhancer | |
| JP2007151436A (en) | Fermented black garlic extract, fermented black garlic powder, production method thereof, and food and drink containing these | |
| JP6490361B2 (en) | Applications of konjac fluid materials | |
| JPH0632802A (en) | Hardly digestible dextrin | |
| FI65014B (en) | FOERFARANDE FOER FRAMSTAELLNING AV BETA-CYKLODEXTRIN-INKLUSIONSKOMPLEX AV NATURLIGA OCH SYNTETISKA AROM- OCH SMAKAEMNEN | |
| CN102125240B (en) | Perpetration method of konjaku can and konjaku can prepared by using same | |
| JP4065834B2 (en) | Tea polysaccharides | |
| JP7744764B2 (en) | Blood sugar level suppressant | |
| JP3902153B2 (en) | Bitter / astringent taste inhibitor | |
| JPH02238856A (en) | Seasoning and condiment containing miraculin as effective component and food and drink containing same | |
| JP4499406B2 (en) | Intestinal function improving agent | |
| JP4431195B2 (en) | Seasoning composition, method for producing the same, and food and drink with improved taste using the seasoning composition | |
| JP5890732B2 (en) | How to improve the flavor of food and drink | |
| JP7545367B2 (en) | Powdered brown algae | |
| JP2005179277A (en) | Fat accumulation inhibitor in the liver | |
| JP2007110982A (en) | Food and drink containing chitosan | |
| JP6888768B2 (en) | Onion powder | |
| KR102951526B1 (en) | Method of sweet potato powder with reduced hardening | |
| KR20150048760A (en) | Noodles containing green leaves of gramineous plant and oligosaccharide | |
| WO2004039176A1 (en) | Quality-improving agent for processed cereal foods and processed cereal food using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240610 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250716 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250909 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250912 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7744764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |